These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33792689)

  • 41. Empagliflozin Attenuates Arrhythmias in an iPSC-Based Model of Hypertrophic Cardiomyopathy.
    Arthur Ataam J; Belbachir N; Perea-Gil I; Termglinchan V; Vadgama N; Garg P; Ramchandani R; Gavidia AA; Roura S; Gálvez-Montón C; Wu JC; Bayés-Genis A; Karakikes I
    Circ Genom Precis Med; 2024 Jun; 17(3):e004526. PubMed ID: 38752368
    [No Abstract]   [Full Text] [Related]  

  • 42. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?
    Baker HE; Tune JD; Goodwill AG; Mather KJ
    J Am Coll Cardiol; 2019 Aug; 74(6):825-826. PubMed ID: 31395139
    [No Abstract]   [Full Text] [Related]  

  • 44. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
    Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
    Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
    Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Forman JL; Møller JE; Schou M
    Circulation; 2021 Jun; 143(22):2208-2210. PubMed ID: 34061581
    [No Abstract]   [Full Text] [Related]  

  • 46. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
    Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
    Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1.
    Mustroph J; Lücht CM; Wagemann O; Sowa T; Hammer KP; Sag CM; Tarnowski D; Holzamer A; Pabel S; Beuthner BE; Sossalla S; Maier LS; Wagner S
    Diabetologia; 2019 Apr; 62(4):726-729. PubMed ID: 30694352
    [No Abstract]   [Full Text] [Related]  

  • 49. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
    J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Empagliflozin, a sodium-glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome.
    Li Y; Zhang Z; Zhang Z; Zheng N; Ding X
    J Cell Physiol; 2024 Jun; 239(6):e31264. PubMed ID: 38764242
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload.
    Makrecka-Kuka M; Korzh S; Videja M; Vilks K; Cirule H; Kuka J; Dambrova M; Liepinsh E
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):791-797. PubMed ID: 32424653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
    Januzzi J; Ferreira JP; Böhm M; Kaul S; Wanner C; Brueckmann M; Petrie MC; Ofstad AP; Zeller C; George J; Fitchett D; Zannad F
    Eur J Heart Fail; 2019 Mar; 21(3):386-388. PubMed ID: 30767353
    [No Abstract]   [Full Text] [Related]  

  • 53. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
    Krasnova M; Kulikov A; Okovityi S; Ivkin D; Karpov A; Kaschina E; Smirnov A
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1649-1658. PubMed ID: 32377771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice?
    Baqai FM; Kitakaze M; Birnbaum Y
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):769-770. PubMed ID: 38888831
    [No Abstract]   [Full Text] [Related]  

  • 57. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
    Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Introduction.
    Chilton R
    Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
    [No Abstract]   [Full Text] [Related]  

  • 59. The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway.
    Zhou Y; Wu W
    Cell Physiol Biochem; 2017; 41(6):2503-2512. PubMed ID: 28472796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
    Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.